pravastatin has been researched along with cerivastatin in 75 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (5.33) | 18.2507 |
| 2000's | 66 (88.00) | 29.6817 |
| 2010's | 5 (6.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buckett, L; Davidson, R; Holdgate, G; McCormick, A; McTaggart, F; Schneck, D; Smith, G; Warwick, M | 1 |
| Hirano, M; Kondo, C; Maeda, K; Matsushima, S; Sasaki, M; Sugiyama, Y; Suzuki, H | 1 |
| Chiba, K; Hosokawa, M; Kameyama, Y; Kobayashi, K; Yamashita, K | 1 |
| Carbonell, T; Freire, E | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Askew, V; Auerbach, B; Bainbridge, G; Caspers, N; Choi, C; Dillon, L; Hanselman, JC; Harris, MS; Hutchings, R; Kowala, M; Larsen, SD; Lin, Z; Lu, GH; Park, W; Pavlovsky, A; Pfefferkorn, JA; Robertson, A; Sekerke, C; Tait, BD | 1 |
| Askew, V; Auerbach, B; Dillon, L; Hanselman, JC; Kennedy, RM; Kowala, MC; Larsen, SD; Lin, Z; Lu, GH; Miller, S; Park, WK; Robertson, A; Roth, BD; Sekerke, C; Song, Y; Steinbaugh, BA; Sun, K; Tait, BD; Trivedi, BK | 1 |
| Ahmad, S; Barrish, JC; Bird, E; Bisaha, S; Blanar, MA; Chang, M; Chen, BC; Chen, X; Cuff, CA; Darienzo, CJ; Giancarli, M; Harrity, T; Huang, C; Janovitz, E; Kennedy, LJ; Li, T; Madsen, CS; Monshizadegan, H; Ngu, K; Nguyen-Tran, V; Reeves, RA; Robl, JA; Ryan, CS; Search, D; Setters, R; Sitkoff, D; Stein, PD; Yin, X; Zahler, R; Zhang, R; Zhao, R; Zhuang, S | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Lopez, D; Ness, GC; Zhao, Z | 1 |
| Davignon, J; Hanefeld, M; Hunninghake, DB; Insull, W; Nakaya, N; Ose, L | 1 |
| Farnier, M | 1 |
| Hoshi, K; Ichihara, K; Satoh, K; Yamamoto, A | 1 |
| Hecker, M; Just, I; Köhler, T; Rückschloss, U; Wagner, AH | 1 |
| Ferdinand, K; Krug-Gourley, S; Poland, M; Saunders, E; Tonkon, MJ; Yellen, LG | 1 |
| Dansette, PM; Jaoen, M; Pons, C | 1 |
| Agarwal, V; Lasseter, KC; Lettieri, J; Mazzu, AL; Shamblen, EC; Sundaresen, P | 1 |
| Dujovne, CA; Hunninghake, D; Knopp, R; Kwiterovich, P; McBride, TA; Poland, M | 1 |
| Ose, L; Risberg, K; Svilaas, A; Thoresen, M | 1 |
| Davidson, MH | 1 |
| Stein, EA | 1 |
| Crouch, MA | 1 |
| Vormfelde, SV | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Maclaine, GD; Patel, H | 1 |
| Gerbes, AL; Parhofer, KG; Schwandt, P; Zachoval, R | 1 |
| Egashira, K; Inoue, S; Kataoka, C; Kitamoto, S; Koyanagi, M; Ni, W; Takeshita, A | 1 |
| Faust, M; Kotzka, J; Krone, W; Müller-Wieland, D | 1 |
| Agro, A; Braeken, A; Hanna, K; McPherson, R | 1 |
| Brazg, R; Dujovne, CA; Insull, W; Isaacsohn, J; Kwiterovich, P; Patrick, MA; Ripa, S; Shan, M; Shugrue-Crowley, E; Stein, E; Tota, R | 1 |
| Igel, M; Sudhop, T; von Bergmann, K | 1 |
| Bazalo, GR | 1 |
| Cohen, LH | 1 |
| Ishibashi, T; Maruyama, Y; Nagata, K; Nakamura, S; Ohkawara, H; Sakamoto, T; Sakurada, S; Shindo, J; Sugimoto, K; Takuwa, Y; Teramoto, T; Yokoyama, K | 1 |
| Auteri, A; Bova, G; Bruni, F; Cercignani, M; Console, E; Palazzuoli, A; Pasqui, AL; Puccetti, L | 1 |
| Hinman, J; Scanu, AM | 1 |
| Ishibashi, T; Maruyama, Y; Nagata, K; Ohkawara, H; Sakamoto, T; Sakurada, S; Shindo, J; Sugimoto, K; Takuwa, Y; Teramoto, T; Yokoyama, K | 1 |
| Ikeda, U; Ito, T; Ohki, R; Shimada, K; Shimpo, M; Takahashi, M; Yamamoto, K | 1 |
| Ikeda, U; Ito, T; Shimada, K; Yamamoto, K | 1 |
| Akimoto, K; Asakawa, H; Horio, T; Matsuoka, H; Minamino, N; Mori, Y; Nishikimi, T; Tadokoro, K; Wang, X; Yoshihara, F | 1 |
| Honda, Y; Honjo, M; Kiryu, J; Nishijima, K; Sawamura, T; Tanihara, H; Yue, BY | 1 |
| Feyen, JH; French, MH; Frith, JC; Güngör, T; Harrity, TW; Rogers, MJ; Staal, A; Swartz, J; Tamasi, J | 1 |
| Gotto, AM | 1 |
| Belenkov, YN; Kaminnyi, AI; Konovalova, GG; Kukharchuk, VV; Lankin, VZ; Pisarenko, OI; Shumaev, KB; Tikhaze, AK | 1 |
| Edwards, JE; Moore, RA | 1 |
| Arai, M; Fujiwara, H; Ito, Y; Kawasaki, M; Minatoguchi, S; Nishigaki, K; Okubo, M; Sano, K; Takemura, G; Uno, Y; Yokoyama, H | 1 |
| Asano, Y; Asanuma, H; Fujita, M; Hirata, A; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Minamino, T; Mori, H; Node, K; Ogai, A; Okuda, H; Sanada, S; Shinozaki, Y; Takashima, S; Tomoike, H | 1 |
| Ilkay Alp, F; Kaleli, D; Ozdemir, O; Sönmez Uydeş-Doğan, B; Takir, S; Topal, G | 1 |
| Carr-Lopez, SM; Elledge, EA; Shinn, AH; Smith, JW; Smith, TJ | 1 |
| Iwano, C; Matsuyama, K; Matzno, S; Nishikata, M; Yasuda, N | 1 |
| Bastemir, M; Emral, R; Gullu, S; Lazarus, JH; Parkes, AB | 1 |
| Corpataux, JM; London, NJ; Naik, J; Porter, KE | 1 |
| Dieleman, JP; Dunselman, H; Straus, SM; Sturkenboom, MC; van Herpen, G; van Wijk, MA; van Wyk, JT | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Foody, JM; Galusha, D; Havranek, EP; Krumholz, HM; Masoudi, FA; Radford, MJ; Rathore, SS | 1 |
| Hayashi, T; Ka, Y; Kitamura, A; Matsumura, Y; Mori, T; Ohkita, M; Sugii, M; Takaoka, M | 1 |
| Brecht, K; Kaufmann, P; Krähenbühl, S; Török, M; Waldhauser, KM; Zahno, A | 1 |
| Mason, RP | 1 |
| Iwano, C; Matsuyama, K; Matzno, S; Tomiyama, N; Yasuda, N | 1 |
| Crockett, JC; Hughes, A; Idris, AI; Rogers, MJ | 1 |
| Dal Pan, G; McAdams, M; Staffa, J | 1 |
| Doney, AS; Donnan, PT; Donnelly, LA; Lang, CC; Morris, AD; Palmer, CN; Whitley, AL | 1 |
| Baker, SK; Isackson, PJ; Peltier, WL; Tarnopolsky, MA; Vladutiu, GD | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Xiao, H; Yang, CS | 1 |
| Bate, A; Edwards, IR; Hägg, S; Strandell, J | 1 |
| Aplin, JD; Forbes, K; Gibson, JM; Shah, VK; Siddals, K; Westwood, M | 1 |
| Cheng, Z; Fu, SW; Hu, B; Ruan, LY; Wang, Y; Zheng, JN; Zheng, MH; Zhou, YY; Zhu, GQ | 1 |
12 review(s) available for pravastatin and cerivastatin
| Article | Year |
|---|---|
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Statin trials in progress: unanswered questions.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
New statins and new doses of older statins.
Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2001 |
Effective use of statins to prevent coronary heart disease.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin | 2001 |
Statin therapy--what now?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
[Cholesterin synthase inhibition and atherosclerosis].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; CCAAT-Enhancer-Binding Proteins; Cholesterol; Cholesterol, LDL; Coenzyme A Ligases; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA Synthase; Hyperlipidemias; Pravastatin; Pyridines; Randomized Controlled Trials as Topic; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2001 |
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Molecular basis of differences among statins and a comparison with antioxidant vitamins.
Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrroles; Vitamins | 2006 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Topics: Atorvastatin; Bayes Theorem; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Liver Neoplasms; Lovastatin; Observational Studies as Topic; Pravastatin; Pyridines; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2016 |
11 trial(s) available for pravastatin and cerivastatin
| Article | Year |
|---|---|
Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies.
Topics: Adolescent; Adult; Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Safety; Simvastatin; Treatment Outcome | 1998 |
Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyridines; Safety; Stereoisomerism; Treatment Outcome; Triglycerides | 2000 |
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Topics: Adult; Anticholesteremic Agents; Antifungal Agents; Area Under Curve; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Pravastatin; Pyridines; Pyrroles; Reference Values; Time Factors | 2000 |
Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group.
Topics: Adolescent; Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Prospective Studies; Pyridines; Treatment Outcome; Triglycerides | 2000 |
Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial.
Topics: Aged; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Cyclosporine; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Pravastatin; Prospective Studies; Pyridines; Time Factors | 2001 |
Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, LDL; Female; Health Care Costs; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyridines; Treatment Outcome | 2001 |
Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia.
Topics: Adolescent; Aged; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyridines | 2001 |
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin; Thrombin; Treatment Outcome | 2001 |
Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2002 |
Different effects of pravastatin and cerivastatin on the media of the carotid arteries as assessed by integrated backscatter ultrasound.
Topics: Aged; Body Mass Index; Carotid Arteries; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pravastatin; Pyridines; Tunica Media; Ultrasonography | 2004 |
In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis.
Topics: Adult; Apoptosis; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Lymphocytes; Male; Middle Aged; Pravastatin; Pyridines; Simvastatin; Thyroid Gland; Thyroiditis, Autoimmune | 2005 |
52 other study(ies) available for pravastatin and cerivastatin
| Article | Year |
|---|---|
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Molecular Structure; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2001 |
Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multid
Topics: Amino Acid Sequence; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bile; Dogs; Humans; Liver; Membrane Transport Proteins; Molecular Sequence Data; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters; Protein Transport; Recombinant Proteins; Transfection | 2005 |
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
Topics: Alleles; Atorvastatin; Biological Transport; Cells, Cultured; Genetic Variation; HeLa Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver-Specific Organic Anion Transporter 1; Mutagenesis, Site-Directed; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyridines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Substrate Specificity; Transfection | 2005 |
Binding thermodynamics of statins to HMG-CoA reductase.
Topics: Atorvastatin; Binding Sites; Calorimetry; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Protein Binding; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thermodynamics | 2005 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hyper
Topics: Animals; Cholesterol, LDL; Cricetinae; Guinea Pigs; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Liver; Male; Mesocricetus; Muscle Cells; Pyrazoles; Rats; Stereoisomerism; Structure-Activity Relationship | 2008 |
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Combinatorial Chemistry Techniques; Disease Models, Animal; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Molecular Structure; Muscle Cells; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with
Topics: Administration, Oral; Animals; Biological Availability; Chemical and Drug Induced Liver Injury; Cholesterol; Crystallography, X-Ray; Dogs; Female; Guinea Pigs; Haplorhini; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Liver; Models, Molecular; Muscle Cells; Pyrimidines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
Topics: Animals; Anticholesteremic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cholesterol; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Male; Pravastatin; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, LDL; RNA, Messenger; Tricarboxylic Acids | 1996 |
[Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?].
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Dogs; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Contraction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Base Sequence; Botulinum Toxins; DNA Primers; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mevalonic Acid; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phorbol 12,13-Dibutyrate; Pravastatin; Protein Kinase C; Pyridines; Pyrroles; Rats; Rats, Wistar; Superoxide Dismutase; Superoxides; Vasodilation | 2000 |
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Topics: Animals; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Microsomes, Liver; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Species Specificity | 2000 |
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Male; Middle Aged; Norway; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Simvastatin; Surveys and Questionnaires | 2000 |
Safety of statins (hydroxymethyl glutaryl coenzyme a reductase inhibitors): different mechanisms of metabolism and drug transport may have clinical relevance.
Topics: Aryl Hydrocarbon Hydroxylases; Biological Availability; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mixed Function Oxygenases; Practice Guidelines as Topic; Pravastatin; Pyridines; Safety; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 2001 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Models, Economic; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Blood Pressure; Chemokine CCL2; Coronary Vessels; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lipids; Macrophages; Male; Monocytes; NG-Nitroarginine Methyl Ester; Nitrates; Nitric Oxide Synthase; Nitrites; Nitroarginine; Peptidyl-Dipeptidase A; Pravastatin; Proliferating Cell Nuclear Antigen; Pyridines; Rats; Rats, Inbred WKY; rhoA GTP-Binding Protein; RNA, Messenger; Systole; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
[Myotoxicity and rhabdomyolisis due to statins].
Topics: Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscles; Pravastatin; Pyridines; Rhabdomyolysis | 2002 |
Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes.
Topics: Acyl Coenzyme A; Analysis of Variance; Base Sequence; Blotting, Western; Cells, Cultured; Coronary Stenosis; Down-Regulation; Humans; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Molecular Sequence Data; Pravastatin; Probability; Protein Serine-Threonine Kinases; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; RNA, Messenger; Sensitivity and Specificity; Thromboplastin | 2002 |
Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; ADP Ribose Transferases; Amides; Arteriosclerosis; Base Sequence; Botulinum Toxins; Cells, Cultured; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Monocytes; Plasminogen Activator Inhibitor 1; Polyisoprenyl Phosphates; Pravastatin; Protein Prenylation; Protein Serine-Threonine Kinases; Pyridines; rho GTP-Binding Proteins; rho-Associated Kinases; RNA, Messenger; Signal Transduction | 2002 |
HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.
Topics: ADP Ribose Transferases; Amides; Analysis of Variance; Animals; Botulinum Toxins; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lovastatin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Protein Serine-Threonine Kinases; Pyridines; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; RNA, Messenger | 2002 |
Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells.
Topics: Analysis of Variance; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-8; Muscle, Smooth, Vascular; Pravastatin; Probability; Pyridines; RNA, Messenger; Sensitivity and Specificity | 2002 |
Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin.
Topics: ADP Ribose Transferases; Amides; Animals; Atrial Natriuretic Factor; Botulinum Toxins; Cell Size; Cells, Cultured; Endothelin-1; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Mevalonic Acid; Myocytes, Cardiac; Phenylalanine; Polyisoprenyl Phosphates; Pravastatin; Protein Serine-Threonine Kinases; Pyridines; Rats; Rats, Wistar; rho GTP-Binding Proteins; rho-Associated Kinases; RNA, Messenger | 2002 |
Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina.
Topics: Acridine Orange; Animals; Apoptosis; Cell Adhesion; Endothelium, Vascular; Fluorescent Dyes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Intercellular Adhesion Molecule-1; Leukocytes; Male; Neurons; Neuroprotective Agents; P-Selectin; Polymerase Chain Reaction; Pravastatin; Pyridines; Rats; Rats, Long-Evans; Reperfusion Injury; Retinal Diseases; Retinal Vessels; RNA, Messenger | 2002 |
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Topics: Animals; Bone Resorption; Calcium; Female; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Osteoclasts; Osteogenesis; Parathyroidectomy; Pravastatin; Protein Prenylation; Pyridines; Rabbits; Rats; Rats, Sprague-Dawley; Simvastatin; Thyroidectomy | 2003 |
Safety and statin therapy: reconsidering the risks and benefits.
Topics: Anticholesteremic Agents; Creatine Kinase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Meta-Analysis as Topic; Muscular Diseases; Pravastatin; Pyridines; Randomized Controlled Trials as Topic; Retrospective Studies; Rhabdomyolysis; Transaminases; Treatment Outcome | 2003 |
Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Topics: Animals; Antioxidants; Arteriosclerosis; Coenzymes; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipoproteins, LDL; Liver; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Probucol; Pyridines; Rats; Time Factors; Ubiquinone; Vitamin E | 2003 |
Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; Androstadienes; Animals; Cardiotonic Agents; Chromones; Coronary Disease; Dogs; Dose-Response Relationship, Drug; Enzyme Activation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Morpholines; Myocardial Infarction; Myocardial Reperfusion Injury; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pravastatin; Pyridines; Quinolines; Signal Transduction; Theophylline; Wortmannin | 2004 |
Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Endothelium, Vascular; Glyburide; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Nitroarginine; Ouabain; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Wistar; Vasodilation | 2005 |
Effects of switching pravastatin to cerivastatin on C-reactive protein, butyrylcholinesterase, and lipids.
Topics: Adult; Aged; Aged, 80 and over; Butyrylcholinesterase; C-Reactive Protein; Female; Humans; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyridines; Risk Factors | 2005 |
Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry.
Topics: Apoptosis; Atorvastatin; Avidin; Biotin; Cell Line; Cell Separation; Cells, Cultured; Drug Industry; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia; Microscopy, Fluorescence; Necrosis; Pharmaceutical Preparations; Pravastatin; Propidium; Pyridines; Pyrroles; Simvastatin; Time Factors | 2005 |
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.
Topics: Atorvastatin; Cell Division; Cell Movement; Chemotaxis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Myocytes, Smooth Muscle; Pravastatin; Pyridines; Pyrroles; Saphenous Vein; Simvastatin | 2005 |
New light on statin side effects. What recent research on the cholesterol drugs means to you.
Topics: Atorvastatin; Biomedical Research; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Differences between statins on clinical endpoints: a population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Endpoint Determination; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Netherlands; Pravastatin; Pyridines; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
Topics: Age Factors; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Drug Prescriptions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Myocardial Infarction; Odds Ratio; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells.
Topics: Animals; Aorta; Atorvastatin; Cells, Cultured; Endothelial Cells; Endothelin-1; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type III; Phosphorylation; Pravastatin; Pyridines; Pyrroles; Quinolines; RNA, Messenger; Swine | 2006 |
Toxicity of statins on rat skeletal muscle mitochondria.
Topics: Animals; Apoptosis; Atorvastatin; Cytochromes c; DNA Fragmentation; Fatty Acids; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Potentials; Mitochondria, Muscle; Mitochondrial Membranes; Muscle, Skeletal; Oxygen; Pravastatin; Pyridines; Pyrroles; Rats; Simvastatin | 2006 |
Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Caspase 3; Cell Line; Clofibrate; DNA Fragmentation; Drug Synergism; Enzyme Activation; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocytes; Pravastatin; Pyridines; Pyrroles | 2007 |
A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
Topics: Anabolic Agents; Animals; Animals, Newborn; Bone and Bones; Bone Resorption; Cells, Cultured; Disease Models, Animal; Female; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred BALB C; Osteoclasts; Osteoporosis; Ovariectomy; Pravastatin; Protein Prenylation; Pyridines; Rabbits; rap1 GTP-Binding Proteins; Signal Transduction; Simvastatin; Water | 2007 |
Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Child; Child, Preschool; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Infant; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Rhabdomyolysis; Simvastatin; United States; United States Food and Drug Administration | 2008 |
Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.
Topics: Anticholesteremic Agents; Apolipoproteins E; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Longitudinal Studies; Male; Middle Aged; Pravastatin; Pyridines; Retrospective Studies; Scotland; Simvastatin; Treatment Outcome | 2008 |
Metabolic myopathies discovered during investigations of statin myopathy.
Topics: Aged; Alleles; Creatine Kinase; DNA; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metabolic Diseases; Middle Aged; Muscular Diseases; Mutation; Neurologic Examination; Pravastatin; Protein Prenylation; Pyridines | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Azithromycin; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin | 2009 |
Statins inhibit insulin-like growth factor action in first trimester placenta by altering insulin-like growth factor 1 receptor glycosylation.
Topics: Female; Glycosylation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin-Like Growth Factor I; Placenta; Pravastatin; Pregnancy; Pregnancy Trimester, First; Pyridines; Receptor, IGF Type 1; Signal Transduction | 2015 |